CAI vs CRSP: Which Stock Is the Better Buy?
Caris Life Sciences, Inc. and CRISPR Therapeutics AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CAI vs CRSP, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Caris Life Sciences, Inc. (CAI) | CRISPR Therapeutics AG (CRSP) | |
|---|---|---|
| Market cap | $5.0B | $4.9B |
| Revenue (latest FY) | $812.03M | $3.51M |
| Net income (latest FY) | $-68.09M | $-581.60M |
| Revenue growth (5y CAGR) | 46.5% | 37.3% |
| Net margin | -8.4% | -16569.8% |
| Return on equity | -11.8% | -30.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | Yes | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full CAI vs CRSP breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CAI's full financials → Open CRSP's full financials →More comparisons
Frequently asked questions
Which is bigger, CAI or CRSP?
Caris Life Sciences, Inc. is larger by market capitalization — $5.0B versus $4.9B.
Which grows faster, CAI or CRSP?
Over the last five fiscal years, Caris Life Sciences, Inc. grew revenue faster — 46.5%/yr versus 37.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
CAI fundamentals → · CRSP fundamentals → · All 1,500+ companies → · Free screener →